BACKGROUND: High-sensitivity cardiac troponin (hs-cTn) assays are now available that can detect measurable troponin in significantly more individuals in the general population than conventional assays. The clinical use of these hs-cTn assays depends on the development of proper reference values. Therefore, our objective was to define hs-cTnI reference values and determinants in the general community, in a healthy reference cohort, and in subsets with diseases. MATERIALS AND METHODS: A well-characterized community-based cohort of 2042 study participants underwent clinical assessment and echocardiographic evaluation. Baseline hs-cTnI measurements were obtained in 1843 individuals. A healthy reference cohort (n = 565) without cardiac, renal, or echocardiographic abnormalities was identified. RESULTS: Measurable hs-cTnI was identified in 1716 (93%) of the community-based study cohort and 499 (88%) of the healthy reference cohort. Parameters that significantly contributed to higher hs-cTnI concentrations in the healthy reference cohort included age, male sex, systolic blood pressure, and left ventricular mass. Glomerular filtration rate and body mass index were not independently associated with hs-cTnI in the healthy reference cohort. Individuals with diastolic and systolic dysfunction, hypertension, and coronary artery disease (but not impaired renal function) had significantly higher hs-cTnI values than the healthy reference cohort. CONCLUSIONS: We assessed an hs-cTnI assay with the aid of echocardiographic imaging in a large, well-characterized community-based cohort. hs-cTnI is remarkably sensitive in the general population, and there are important sex and age differences among healthy reference individuals. These results have important implications for defining hs-cTnI reference values and identifying disease.
BACKGROUND: High-sensitivity cardiac troponin (hs-cTn) assays are now available that can detect measurable troponin in significantly more individuals in the general population than conventional assays. The clinical use of these hs-cTn assays depends on the development of proper reference values. Therefore, our objective was to define hs-cTnI reference values and determinants in the general community, in a healthy reference cohort, and in subsets with diseases. MATERIALS AND METHODS: A well-characterized community-based cohort of 2042 study participants underwent clinical assessment and echocardiographic evaluation. Baseline hs-cTnI measurements were obtained in 1843 individuals. A healthy reference cohort (n = 565) without cardiac, renal, or echocardiographic abnormalities was identified. RESULTS: Measurable hs-cTnI was identified in 1716 (93%) of the community-based study cohort and 499 (88%) of the healthy reference cohort. Parameters that significantly contributed to higher hs-cTnI concentrations in the healthy reference cohort included age, male sex, systolic blood pressure, and left ventricular mass. Glomerular filtration rate and body mass index were not independently associated with hs-cTnI in the healthy reference cohort. Individuals with diastolic and systolic dysfunction, hypertension, and coronary artery disease (but not impaired renal function) had significantly higher hs-cTnI values than the healthy reference cohort. CONCLUSIONS: We assessed an hs-cTnI assay with the aid of echocardiographic imaging in a large, well-characterized community-based cohort. hs-cTnI is remarkably sensitive in the general population, and there are important sex and age differences among healthy reference individuals. These results have important implications for defining hs-cTnI reference values and identifying disease.
Authors: Bernhard M Kaess; Tonia de Las Heras Gala; Astrid Zierer; Christa Meisinger; Simone Wahl; Annette Peters; John Todd; Christian Herder; Cornelia Huth; Barbara Thorand; Wolfgang Koenig Journal: Eur J Epidemiol Date: 2017-06-05 Impact factor: 8.082
Authors: Olga Rodenko; Susann Eriksson; Peter Tidemand-Lichtenberg; Carl Peder Troldborg; Henrik Fodgaard; Sylvana van Os; Christian Pedersen Journal: Biomed Opt Express Date: 2017-07-20 Impact factor: 3.732
Authors: Paul M McKie; Omar F AbouEzzeddine; Christopher G Scott; Ramila Mehta; Richard J Rodeheffer; Margaret M Redfield; John C Burnett; Allan S Jaffe Journal: Clin Chem Date: 2014-07-01 Impact factor: 8.327
Authors: Daniel Soetkamp; Koen Raedschelders; Mitra Mastali; Kimia Sobhani; C Noel Bairey Merz; Jennifer Van Eyk Journal: Expert Rev Proteomics Date: 2017-10-16 Impact factor: 3.940
Authors: M Odette Gore; Stephen L Seliger; Christopher R Defilippi; Vijay Nambi; Robert H Christenson; Ibrahim A Hashim; Ron C Hoogeveen; Colby R Ayers; Wensheng Sun; Darren K McGuire; Christie M Ballantyne; James A de Lemos Journal: J Am Coll Cardiol Date: 2014-02-12 Impact factor: 24.094